COBIK

🔊 Proud to be part of this inspiring story!

COBIK’s Expertise in 𝗣𝗹𝗮𝘀𝗺𝗶𝗱 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴: A Foundation for successful development and clinical trials Excited to share more about COBIK’s role in the successful Phase I trial using the phIL12 plasmid (https://lnkd.in/esvQB44e) by Institute of Oncology Ljubljana! Our expertise in plasmid manufacturing enabled us to develop an optimized pDNA production process (https://lnkd.in/eGpfqt2K) that supported this important clinical study.  Since then, we have 𝗱𝗿𝗮𝘀𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗲𝘅𝗽𝗮𝗻𝗱𝗲𝗱 𝗼𝘂𝗿 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗮𝗻𝗱 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 in nucleic acid manufacturing. Scalable and high yielding 𝗳𝗲𝗱-𝗯𝗮𝘁𝗰𝗵 𝗳𝗲𝗿𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 is the foundation of our plasmid manufacturing, but our focus extends beyond just increasing yield. While higher productivity brings 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆, 𝗹𝗼𝘄𝗲𝗿 𝗰𝗼𝘀𝘁𝘀, 𝗮𝗻𝗱 𝗳𝗮𝘀𝘁𝗲𝗿 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲𝘀, our true goal is to 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗮𝗻𝗱 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗲 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 𝘁𝗮𝗶𝗹𝗼𝗿𝗲𝗱 𝘁𝗼 𝘁𝗵𝗲 𝘂𝗻𝗶𝗾𝘂𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗼𝗳 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗽𝗹𝗮𝘀𝗺𝗶𝗱 𝘃𝗲𝗰𝘁𝗼𝗿𝘀—ensuring they meet the highest standards for their intended applications. We dedicate our efforts to tackle plasmid specific challenges, including: ✅ 𝗥𝗲𝗱𝘂𝗰𝗶𝗻𝗴 𝗺𝘂𝗹𝘁𝗶𝗺𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 in mRNA vectors to enhance mRNA quality and safety ✅ 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝘃𝗲𝗰𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 𝘁𝗵𝗮𝘁 𝗲𝗻𝘀𝘂𝗿𝗲 𝗽𝗼𝗹𝘆𝗔 𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 during manufacturing, supporting robust and reliable mRNA production ✅ 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝗔𝗔𝗩 𝘃𝗲𝗰𝘁𝗼𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 by developing processes to maintain high ITR integrity ✅ 𝗥𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗽𝘂𝗿𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀, implementing a two-step process to achieve >𝟵𝟵% 𝘀𝘂𝗽𝗲𝗿𝗰𝗼𝗶𝗹𝗲𝗱 𝗽𝘂𝗿𝗶𝘁𝘆 By integrating advanced analytics and continuous improvement, we ensure that every plasmid is manufactured with scalability in mind while maintaining the highest quality standards. From 𝘃𝗲𝗰𝘁𝗼𝗿 𝗱𝗲𝘀𝗶𝗴𝗻 𝗮𝗻𝗱 𝗰𝗹𝗼𝗻𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 to 𝘂𝗽𝘀𝘁𝗿𝗲𝗮𝗺 𝗮𝗻𝗱 𝗱𝗼𝘄𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗶𝗻𝗴, followed by in-depth 𝗮𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝘀, we deliver 𝗵𝗶𝗴𝗵-𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗽𝗹𝗮𝘀𝗺𝗶𝗱𝘀 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝘃𝗮𝗰𝗰𝗶𝗻𝗲𝘀. We're excited to bring our expertise to the community and continue driving innovation in nucleic acid manufacturing!   #PlasmidManufacturing #GeneTherapy #mRNA #pDNA #AAV #Bioprocessing

Throwback to last week’s 𝟮𝗻𝗱 𝗦𝗹𝗼𝘃𝗲𝗻𝗶𝗮𝗻 𝗣𝗵𝗮𝗴𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴! We had an incredible time exchanging ideas and exploring the latest advancements in bacteriophage research. The event was filled with insightful presentations and dynamic discussions, reinforcing the importance of phage therapy in modern medicine. COBIK was proud to present our work on the production of 𝘚. 𝘦𝘱𝘪𝘥𝘦𝘳𝘮𝘪𝘥𝘪𝘴 bacteriophage, which was successfully used as an unlicensed medicine for a patient in special clinical need in the UK. Seeing phage therapy make a real-world impact is truly inspiring! Looking forward to the next Slovenian Phage Meeting and the exciting collaborations it will spark! #Bacteriophages #Meeting #Phages 

🔊 Excited to be part of the 𝟮𝗻𝗱 𝗦𝗹𝗼𝘃𝗲𝗻𝗶𝗮𝗻 𝗣𝗵𝗮𝗴𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 at the University of Ljubljana, Biotechnical Faculty!   🔉 The event kicked off with an opening session by Rob Lavigne, who delivered an insightful lecture on phage biology and its diverse applications. 🔉 We’re especially looking forward to the 3rd session at 4 PM, where our very own Martina Durcik will present the recently published clinical use of 𝗦. 𝗲𝗽𝗶𝗱𝗲𝗿𝗺𝗶𝗱𝗶𝘀 𝗽𝗵𝗮𝗴𝗲𝘀, along with the research and development journey behind it.   #Bacteriophages #PhageTherapy #Sepidermidis #Meeting #COBIK

🌟 COBIK Phages Are Reaching Patients! 🌟 At COBIK, we’ve dedicated over a decade to advancing phage science, isolating numerous bacteriophages, and conducting rigorous preclinical testing on animal models. Our unwavering focus has been on ensuring the therapeutic suitability and uncompromising quality of phage products. We are thrilled to share that 𝗖𝗢𝗣-𝟴𝟬𝗕, a bacteriophage isolated, characterized, and manufactured by COBIK, was successfully used to treat a patient with a 𝗽𝗲𝗿𝗶𝗽𝗿𝗼𝘀𝘁𝗵𝗲𝘁𝗶𝗰 𝗷𝗼𝗶𝗻𝘁 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 in the right knee. 📄 The case is detailed in a recent publication: https://lnkd.in/eg8e53RF In short, there was no adverse effects and six months post-treatment, the patient is 𝗽𝗮𝗶𝗻-𝗳𝗿𝗲𝗲 with a 𝗳𝘂𝗹𝗹𝘆 𝗵𝗲𝗮𝗹𝗲𝗱 𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝘄𝗼𝘂𝗻𝗱. This successful treatment reflects our unwavering commitment to improving patients' lives and the incredible partnerships that have made it possible. We extend our heartfelt gratitude to: 🤝 𝗝𝗼𝘀𝗵 𝗝𝗼𝗻𝗲𝘀 from UK Phage Therapy 🤝 Our Slovenian collaborators: BIA Separations Inc. (Sartorius), Nika Janez, University of Ljubljana, Biotechnical Faculty and Ortopedska bolnišnica Valdoltra Ankaran Slovenia. Together, we are paving the way for innovative solutions to combat antimicrobial resistance. 🔬 Stay tuned as we continue to push the boundaries of bacteriophage research and therapy! #Bacteriophage #PhageTherapy #Innovation #AntimicrobialResistance #COBIK #Collaboration

🔊 Less than a week to go! 🔊 📅 We’re counting down to the 𝟮𝗻𝗱 𝗦𝗹𝗼𝘃𝗲𝗻𝗶𝗮𝗻 𝗣𝗵𝗮𝗴𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 on 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟮𝟯, 𝟮𝟬𝟮𝟱! COBIK is pleased to be part of this exciting event, where our colleague Martina Durcik will present our latest advancements in the dynamic field of 𝗽𝗵𝗮𝗴𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁. This is a fantastic opportunity to connect, network, and collaborate with fellow phage enthusiasts from academia and industry. 🔊 A special shoutout to Anna Dragos, University of Ljubljana, Biotechnical Faculty, JAFRAL Biosolutions and University of Ljubljana, Faculty of Chemistry and Chemical Technology for their contributions to making this event possible. Looking forward to seeing you there! https://lnkd.in/dVwvMJNu #PhageResearch #PhageInnovation #Networking #ScientificCommunity

🔊 Developing an efficient and scalable manufacturing process for high-quality plasmid DNA is a complex and challenging task. The COBIK team is proud to have contributed to this groundbreaking study by developing a superior manufacturing process for IL-12 plasmid DNA. 🔊 Congratulations to the Institute of Oncology Ljubljana on achieving this significant milestone in advancing cancer treatment, and heartfelt thanks to all the partners who played a crucial role in this success. JAFRAL Biosolutions, Iskra PIO University of Ljubljana, Faculty of Electrical Engineering, Institute of Oncology Ljubljana #COBIK #plasmid #Manufacturing #BioprocessDevelopment #GeneTherapy #CancerResearch #ClinicalTrials #electroporation #interleukin12

🔊 Congratulations to our colleague Urban Bezeljak for having the most cited article in Radiology and Oncology titled "Cancer gene therapy goes viral: viral vector platforms come of age"! Check out his article through the link below! ⬇ https://lnkd.in/ebrzZtxs #COBIK #Oncology #article #genetherapy

🔊 We are thrilled to announce our contribution to the Slovenian Veterinary Research journal with our editorial, ‘Rediscovering Phage Therapy: A Promising Approach for Combating Antimicrobial Resistance.’ ⚗ 🔊 In this piece, we highlight the critical issue of antimicrobial resistance and explore how phage therapy could be a powerful solution. We also examine its applications in veterinary medicine and discuss the current regulatory landscape for phage product development.🐶🐱🐴 🔊 For a deeper dive into the potential of phage therapy in small animal veterinary medicine, check out also the article, ‘Skin Dysbiosis in Atopic Dogs: Is Phage Therapy an Alternative to Antibiotics?’ here: https://lnkd.in/ewxBWMbB. #COBIK #phagetherapy #veterinarymedicine #antimicrobialresistance #research